CrystalGenomics Inc Net Assets

Latest as of September 2025: ₩87.96 Billion KRW ≈ $59.61 Million USD

CrystalGenomics Inc net assets. Based on the latest financial reports, CrystalGenomics Inc (083790) has net assets worth ₩87.96 Billion KRW (≈ $59.61 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩212.20 Billion ≈ $143.81 Million USD) and total liabilities (₩124.24 Billion ≈ $84.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CrystalGenomics Inc annual equity growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩87.96 Billion
% of Total Assets	41.45%
Annual Growth Rate	9.47%
5-Year Change	-54.13%
10-Year Change	36.94%
Growth Volatility	38.93

Net Assets of CrystalGenomics Inc (2011–2024)

Net assets of CrystalGenomics Inc from 2011 to 2024. This chart illustrates how CrystalGenomics Inc's net assets have evolved over time, based on quarterly financial data. See how leveraged is CrystalGenomics Inc's balance sheet to measure how much of total assets are equity-financed.

Annual Net Assets for CrystalGenomics Inc (2011–2024)

The table below shows the annual net assets of CrystalGenomics Inc from 2011 to 2024. For live market cap and overall valuation, see CrystalGenomics Inc market capitalisation.

Year	Net Assets	Change
2024-12-31	₩98.52 Billion ≈ $66.76 Million	-32.19%
2023-12-31	₩145.29 Billion ≈ $98.46 Million	-22.83%
2022-12-31	₩188.28 Billion ≈ $127.59 Million	-9.41%
2021-12-31	₩207.84 Billion ≈ $140.85 Million	-3.22%
2020-12-31	₩214.76 Billion ≈ $145.54 Million	+44.09%
2019-12-31	₩149.05 Billion ≈ $101.01 Million	-19.20%
2018-12-31	₩184.47 Billion ≈ $125.01 Million	+101.41%
2017-12-31	₩91.59 Billion ≈ $62.07 Million	+10.14%
2016-12-31	₩83.16 Billion ≈ $56.36 Million	+15.59%
2015-12-31	₩71.94 Billion ≈ $48.75 Million	+30.74%
2014-12-31	₩55.03 Billion ≈ $37.29 Million	+52.16%
2013-12-31	₩36.16 Billion ≈ $24.51 Million	+62.40%
2012-12-31	₩22.27 Billion ≈ $15.09 Million	-26.68%
2011-12-31	₩30.37 Billion ≈ $20.58 Million	--

Equity Component Analysis

This analysis shows how different components contribute to CrystalGenomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1454.0% over the analyzed period, potentially due to dividend distributions or operating losses.

CrystalGenomics Inc Net Assets Breakdown (December 2024)

CrystalGenomics Inc net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Common Stock	₩38.45 Billion	39.03%
Other Components	₩73.60 Billion	74.71%
Total Equity	₩98.52 Billion	100.00%

CrystalGenomics Inc Competitors by Market Cap

The table below lists competitors of CrystalGenomics Inc ranked by their market capitalization.

Company	Market Cap
Makina Takim Endustrisi AS IS:MAKTK	$22.71 Million
Obducat AB (publ) F:OBD	$22.71 Million
Pelayaran Nelly Dwi Putri Tbk JK:NELY	$22.72 Million
Mmcité a.s. PR:MMCTE	$22.73 Million
Econframe Bhd KLSE:0227	$22.69 Million
Data I/O Corporation NASDAQ:DAIO	$22.68 Million
Asiaplast Industries Tbk JK:APLI	$22.68 Million
Ram Technology Co. Ltd KQ:171010	$22.67 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CrystalGenomics Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 145,292,993,240 to 98,517,864,340, a change of -46,775,128,900 (-32.2%).
Net loss of 51,544,107,400 reduced equity.
Dividend payments of 2,520,000,000 reduced retained earnings.
Other factors increased equity by 7,288,978,500.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-51.54 Billion	-52.32%
Dividends Paid	₩2.52 Billion	-2.56%
Other Changes	₩7.29 Billion	+7.4%
Total Change	₩-	-32.19%

Book Value vs Market Value Analysis

This analysis compares CrystalGenomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.65x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.51x to 0.65x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1610.96	₩828.00	x
2017-12-31	₩1692.22	₩828.00	x
2018-12-31	₩3044.88	₩828.00	x
2019-12-31	₩2400.79	₩828.00	x
2020-12-31	₩3102.05	₩828.00	x
2021-12-31	₩3072.05	₩828.00	x
2022-12-31	₩2732.32	₩828.00	x
2023-12-31	₩1898.18	₩828.00	x
2024-12-31	₩1281.21	₩828.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently CrystalGenomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -52.32%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -710.63%
• Asset Turnover: 0.03x
• Equity Multiplier: 2.64x
Recent ROE (-52.32%) is below the historical average (-15.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-21.68%	-263.05%	0.04x	1.93x	₩-17.43 Billion
2015	-6.74%	-79.04%	0.05x	1.77x	₩-12.04 Billion
2016	-2.62%	-15.00%	0.11x	1.55x	₩-10.50 Billion
2017	-9.36%	-70.43%	0.10x	1.30x	₩-17.73 Billion
2018	3.74%	49.74%	0.05x	1.39x	₩-11.54 Billion
2019	-25.22%	-268.34%	0.04x	2.54x	₩-52.49 Billion
2020	-4.58%	-32.55%	0.10x	1.48x	₩-31.31 Billion
2021	-7.65%	-37.52%	0.13x	1.60x	₩-36.68 Billion
2022	-12.68%	-552.35%	0.01x	1.71x	₩-42.70 Billion
2023	-33.67%	-1002.81%	0.02x	1.67x	₩-63.45 Billion
2024	-52.32%	-710.63%	0.03x	2.64x	₩-61.40 Billion

Industry Comparison

This section compares CrystalGenomics Inc's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $101,034,626,727
Average return on equity (ROE) among peers: 12.99%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
CrystalGenomics Inc (083790)	₩87.96 Billion	-21.68%	1.41x	$22.70 Million
Sam Chun Dang Pharm. Co. Ltd (000250)	$266.11 Billion	-4.10%	0.95x	$2.49 Billion
DongKoo Bio & Pharma Co. Ltd. (006620)	$2.55 Billion	158.01%	22.83x	$21.80 Million
NatureCell Co.Ltd (007390)	$13.75 Billion	13.78%	0.78x	$793.12 Million
Sam-A Pharm. Co. Ltd (009300)	$200.47 Billion	10.66%	0.15x	$56.13 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$259.82 Billion	4.88%	0.12x	$78.42 Million
WooGene B&G Co. Ltd (018620)	$27.27 Billion	-46.89%	2.12x	$46.98 Million
Oscotec Inc (039200)	$21.78 Billion	-9.28%	0.67x	$674.16 Million
EstechPharma Co. Ltd (041910)	$115.63 Billion	3.31%	0.05x	$42.90 Million
Komipharm International Co. Ltd (041960)	$60.02 Billion	-6.63%	0.98x	$343.99 Million
Eagle Veterinary Technology Co.Ltd (044960)	$42.95 Billion	6.15%	0.28x	$25.96 Million

About CrystalGenomics Inc

KQ:083790 Korea Pharmaceuticals

Market Cap

$22.70 Million

₩33.49 Billion KRW

Market Cap Rank

#24542 Global

#1759 in Korea

Share Price

₩828.00

Change (1 day)

-2.59%

52-Week Range

₩744.00 - ₩1637.00

All Time High

₩18365.04